NASDAQ:NTLA - Intellia Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $26.78 -4.73 (-15.01 %) (As of 09/21/2018 04:00 PM ET)Previous Close$26.78Today's Range$26.74 - $31.5152-Week Range$16.33 - $35.99Volume2.67 million shsAverage Volume472,896 shsMarket Capitalization$1.36 billionP/E Ratio-14.24Dividend YieldN/ABeta3.09 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. Receive NTLA News and Ratings via Email Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical SymbolNASDAQ:NTLA CUSIPN/A Webwww.intelliatx.com Phone857-285-6200 Debt Debt-to-Equity RatioN/A Current Ratio12.62 Quick Ratio12.62 Price-To-Earnings Trailing P/E Ratio-14.24 Forward P/E Ratio-13.59 P/E GrowthN/A Sales & Book Value Annual Sales$26.12 million Price / Sales44.29 Cash FlowN/A Price / CashN/A Book Value$8.33 per share Price / Book3.21 Profitability EPS (Most Recent Fiscal Year)($1.88) Net Income$-67,540,000.00 Net Margins-284.56% Return on Equity-31.54% Return on Assets-25.03% Miscellaneous Employees195 Outstanding Shares43,200,000Market Cap$1.36 billion Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions What is Intellia Therapeutics' stock symbol? Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA." How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings results on Wednesday, August, 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $6.39 million. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The firm's revenue for the quarter was up 30.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. View Intellia Therapeutics' Earnings History. When is Intellia Therapeutics' next earnings date? Intellia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Intellia Therapeutics. What price target have analysts set for NTLA? 10 brokers have issued 1-year price targets for Intellia Therapeutics' stock. Their predictions range from $28.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $41.0833 in the next year. This suggests a possible upside of 53.4% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics. What is the consensus analysts' recommendation for Intellia Therapeutics? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics. What are Wall Street analysts saying about Intellia Therapeutics stock? Here are some recent quotes from research analysts about Intellia Therapeutics stock: 1. Chardan Capital analysts commented, "We note Intellia is collaborating with the same research group at the Saraiva, who worked with Alnylam during the preclinical development of its RNAi-based therapeutics to treat ATTR. In 2010, Alnylam presented preclinical data (1, 2), also using the Porto group’s transgenic V30M mouse model, showing reductions of TTR deposition of >95% after siRNA administration every 2 weeks. Importantly, with 1 siRNA dose, TTR protein levels began to rebound within 8 days after treatment. In contrast, 1 dose of Intellia’s LNP-delivered CRISPR/Cas agent resulted in stable knockdown over 12 months, underscoring the potential advantage of the permanent nature of gene editing, though more durable RNAi formulations are now in development." (8/24/2018) 2. According to Zacks Investment Research, "Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. " (8/7/2018) 3. Cann analysts commented, "Update highlights include advancement in ex vivo development and expectations for timing of first IND. Loss per share was $0.51 compared to our estimated loss of $0.44 This primarily was the result of higher R&D of $22.5 million compared to our estimate of $19.0 million; and was partially offset by higher than expected interest income. Our revenue outlook for 2018-22 remains unchanged. We are modestly decreasing our estimated shares outstanding in 2018-22; as a result, we are making very slight adjustments to our estimated loss per share in 2019-22." (5/1/2018) Who are some of Intellia Therapeutics' key competitors? Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Vermillion (VRML), ImmuCell (ICCC) and Akers Biosciences (AKER). Who are Intellia Therapeutics' key executives? Intellia Therapeutics' management team includes the folowing people: Dr. John M. Leonard, Pres, CEO & Director (Age 61)Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 45)Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 52)Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 32)Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board When did Intellia Therapeutics IPO? (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Has Intellia Therapeutics been receiving favorable news coverage? Headlines about NTLA stock have been trending somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Intellia Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Intellia Therapeutics. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (10.45%), BlackRock Inc. (5.92%), FMR LLC (5.85%), Morgan Stanley (5.17%), Atlas Venture Associates IX LLC (4.26%) and Orbimed Advisors LLC (2.03%). Company insiders that own Intellia Therapeutics stock include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard, Nessan Bermingham and Venture Fund Ix LP Atlas. View Institutional Ownership Trends for Intellia Therapeutics. Which major investors are selling Intellia Therapeutics stock? NTLA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Atlas Venture Associates IX LLC, Baker BROS. Advisors LP, Orbimed Advisors LLC and Raymond James & Associates. Company insiders that have sold Intellia Therapeutics company stock in the last year include Caribou Biosciences, Inc, Institutes For Biomed Novartis, Jean Francois Formela, John M Leonard and Nessan Bermingham. View Insider Buying and Selling for Intellia Therapeutics. Which major investors are buying Intellia Therapeutics stock? NTLA stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Morgan Stanley, Northern Trust Corp, Bank of America Corp DE, First Trust Advisors LP, Chevy Chase Trust Holdings Inc. and Korea Investment CORP. View Insider Buying and Selling for Intellia Therapeutics. How do I buy shares of Intellia Therapeutics? Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intellia Therapeutics' stock price today? One share of NTLA stock can currently be purchased for approximately $26.78. How big of a company is Intellia Therapeutics? Intellia Therapeutics has a market capitalization of $1.38 billion and generates $26.12 million in revenue each year. The company earns $-67,540,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Intellia Therapeutics employs 195 workers across the globe. How can I contact Intellia Therapeutics? Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected] MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 214 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 386MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?